Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase
- Authors:
- Eiseki Usami
- Michio Kimura
- Mina Iwai
- Hitomi Teramachi
- Tomoaki Yoshimura
View Affiliations
Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan, Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu 501‑1196, Japan
- Published online on: April 28, 2017 https://doi.org/10.3892/mco.2017.1232
-
Pages:
955-959
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The purpose of this study was to assess the incidence of tumor lysis syndrome (TLS) in patients with hematological malignancies treated with rasburicase, and to evaluate the dose and duration of rasburicase administration. A total of 52 patients were enrolled. The background of the patients, incidence of TLS and laboratory data were retrospectively examined; in addition, the dose and duration of rasburicase administration and the factors affecting the onset of TLS were evaluated and compared among TLS risk categories. During the study period, 2 (3.8%) of the patients developed clinical TLS and 24 (46.2%) developed laboratory TLS (LTLS). Although the LTLS rate was very high, there were no life‑threatening cases of TLS. The median daily dose of rasburicase administered to all patients was 7.5 mg/day (interquartile range, 7.5‑9.0 mg/day), and the daily weight‑based dose was 0.147 mg/kg/day (range, 0.126‑0.178 mg/kg/day). The administration duration was 3 days (interquartile range, 3‑4 days). Additionally, there was no significant association between TLS risk classification and daily rasburicase administration dose, duration, or post‑administration laboratory data. The factors affecting the onset of TLS included serum uric acid level, as well as serum creatinine and phosphate levels. Rasburicase was highly effective in the prevention and management of hyperuricemia, even at a low‑dose (7.5 mg/day) and a duration that was 3 days shorter compared with that recommended by the manufacturer. Therefore, clinicians should administer rasburicase based on their clinical judgment, taking into consideration the cost‑effectiveness of this therapy.
View References
1
|
Bessmertny O, Robitaille LM and Cairo MS:
Rasburicase: A new approach for preventing and/or treating tumor
lysis syndrome. Curr Pharm Des. 11:4177–4185. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hochberg J and Cairo MS: Tumor lysis
syndrome: Current perspective. Haematologica. 93:9–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Coiffier B, Altman A, Pui CH, Younes A and
Cairo MS: Guidelines for the management of pediatric and adult
tumor lysis syndrome: An evidence-based review. J Clin Oncol.
26:2767–2778. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Oldfield V and Perry CM: Rasburicase: A
review of its use in the management of anticancer therapy-induced
hyperuricaemia. Drugs. 66:529–545. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Feng X, Dong K, Pham D, Pence S, Inciardi
J and Bhutada NS: Efficacy and cost of single-dose rasburicase in
prevention and treatment of adult tumour lysis syndrome: A
meta-analysis. J Clin Pharm Ther. 38:301–308. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
McBride A, Lathon SC, Boehmer L, Augustin
KM, Butler SK and Westervelt P: Comparative evaluation of single
fixed dosing and weight-based dosing of rasburicase for tumor lysis
syndrome. Pharmacotherapy. 33:295–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Reeves DJ and Bestul DJ: Evaluation of a
single fixed dose of rasburicase 7.5 mg for the treatment of
hyperuricemia in adults with cancer. Pharmacotherapy. 28:685–690.
2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cairo MS, Coiffier B, Reiter A and Younes
A: TLS Expert Panel: Recommendations for the evaluation of risk and
prophylaxis of tumour lysis syndrome (TLS) in adults and children
with malignant diseases: An expert TLS panel consensus. Br J
Haematol. 149:578–586. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Mughal TI, Ejaz AA, Foringer JR and
Coiffier B: An integrated clinical approach for the identification,
prevention, and treatment of tumor lysis syndrome. Cancer Treat
Rev. 36:164–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Campara M, Shord SS and Haaf CM:
Single-dose rasburicase for tumour lysis syndrome in adults:
Weight-based approach. J Clin Pharm Ther. 34:207–113. 2009.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Herrington JD and Dinh BC2: Fixed,
low-dose rasburicase for the treatment or prevention of
hyperuricemia in adult oncology patients. J Oncol Pharm Pract.
21:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
|